Excelra Earns Acclaim from Frost & Sullivan for its GOBIOM Database, the World's Largest Repository of Clinical, Pre-Clinical, and Exploratory Biomarkers

The GOBIOM platform's content for biomarker assay techniques can alleviate the risks associated with biomarker-based clinical trials

MOUNTAIN VIEW, Calif. - November 21, 2016 - Based on its recent analysis of the biomarker research market, Frost & Sullivan recognizes Excelra Knowledge Solutions Pvt. Ltd. with the 2016 North American Frost & Sullivan Award for Enabling Technology Leadership. Excelra's comprehensive, content-rich biomarker database platform, the Global Online Biomarker Database (GOBIOM), is one of the largest biomarker database platforms in the world. It covers 2,000 therapeutic indications with more than 95,000 genomic, proteomic, metabolomic, clinical scoring scales, imaging, biochemical, and cellular biomarkers.

"GOBIOM's biomarkers are manually curated from an extensive range of resources, including scientific publications, clinical trials, meeting conferences, patents, and regulatory documents," said Frost & Sullivan Research Analyst Vandana Iyer. "Unlike its competitors, it has detailed descriptions of biomarker validation protocols that include records of sensitivity and the specificity of varied biomarker assays. This can increase the success rates of biomarker-based clinical trials."

The GOBIOM platform features an intuitive user interface that offers basic, advanced, and batch queries for rapid access to biomarker data. This unique database also provides a robust analytical platform to aid efficient data visualization and acquire valuable insights on biomarker applications. Additionally, GOBIOM features a heat map visualization tool that facilitates the identification of biomarker trends across a range of indications, and a graphical representation of biomarker roles in disease pathogenesis.

The GOBIOM database uses a standard nomenclature throughout the platform and relevant biomarker information can be readily extracted into a user-preferred format. Its meticulous classification of datasets is based on the nature and utility of the biomarker. Furthermore, the biomarker data can be mapped to its approval status, experimental methodologies, clinical trial information, interventional strategies, and preclinical studies.

"In 2008, Excelra began its collaboration with the US Food and Drug Administration to develop content related to drug-induced toxicity and safety biomarkers," noted Iyer. "This collaboration accelerated the transformation of the GOBIOM platform to a highly evolved database consisting of standardized ontology, numerous biomarker utilities, and normalized biomarker classification."

The GOBIOM platform can be used across a wide range of applications such as:

  • Drug discovery and development research
  • Drug toxicity analyses
  • Drug resistance and efficacy studies
  • Drug metabolism research
  • Diagnostic analyses
  • System biology research

Biomarker utilities assigned in the GOBIOM platform include:

  • Diagnosis
  • Prognosis
  • Monitoring disease progression
  • Monitoring or predicting treatment efficacy
  • Identification of surrogate endpoints in clinical trials
  • Analysis of drug safety, toxicity, and pharmacokinetic profiles
  • Evaluating drug resistance
  • Assessment of clinical scoring scales

Furthermore, the GOBIOM data can be utilized to analyze epigenetic biomarkers for research across systems biology. Its application scope extends to research scientists, clinicians, and system biologists, as well as diagnostic and pharmaceutical establishments.

Excelra has a dedicated team of more than 650 scientific experts in the field of clinical studies, chemistry, and biology who meticulously develop content for the company's proprietary database platforms. Its several database platforms are used for several scientific publications and serve as industry standards in various settings.

Each year, Frost & Sullivan presents this award to a company that has developed a pioneering technology that not only enhances current products, but also enables the development of newer products and applications. The award recognizes the high market acceptance potential of the recipient's technology.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Excelra Knowledge Solutions Pvt. Ltd.

Excelra Knowledge Solutions (formerly GVK Informatics) is a leading scientific informatics solutions company that provides intelligent data indexing, abstraction and analytics solutions to a global customer base. The company leverages the expertise over 650 scientists to curate comprehensive databases that include SAR (GOSTAR), Biomarkers (GOBIOM) and Clinical outcomes. Excelra's client base includes some of the world's largest pharma, agrochemical, biotech, life sciences, regulatory, and academic establishments across US, Europe and Asia Pacific regions.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community.

For more information Contact:
Jesintha Mary Maniraja
Director, GOBIOM
Excelra Knowledge Solutions Pvt. Ltd
T: +91 (0) 80. 6707 3333
E: jesintha.maniraja@excelra.com

Scroll To Top